Press Releases

• 2019
• 2018

• September 19

  Celsius Therapeutics Signs Multiple Agreements with Academic Institutions to Access Samples for the Identification of Novel Targets in Immune Checkpoint Therapy Resistance

  Celsius Applying its Single-Cell Genomics Platform Across Multiple Tumor Types and Immuno-Oncology Clinical Trials CAMBRIDGE, Mass., September 19, 2019 – Celsius Therapeutics, a company focused on bringing personalized medicine to patients with cancer, autoimmunity and other complex diseases, today announced the signing of collaboration agreements with the Parker Institute for Cancer Immunotherapy (San Francisco, USA), Institut […]

• July 9

  Celsius Therapeutics Signs Collaboration Agreement with Janssen to Identify Response Biomarkers for Ulcerative Colitis

  Celsius to Apply its Single-Cell Genomics and Machine Learning Platform at Unprecedented Scale in Large Phase 2 Clinical Study CAMBRIDGE, Mass., July 9, 2019 – Celsius Therapeutics, a company focused on the discovery and development of precision therapeutics for patients with autoimmune diseases and cancer, today announced a collaboration with Janssen Biotech, Inc. Under the terms […]

• June 11

  Celsius Therapeutics Appoints Tariq Kassum, M.D., as Chief Executive Officer

  Experienced biopharma leader brings business development, strategy and company-building expertise to accelerate Celsius’ growth

• May 22

  Celsius Therapeutics Announces Executive Leadership Team Appointments

  Greg Ryslik, Ph.D., Appointed to Chief Data Officer
  Michael Boretti, Ph.D., Appointed to Chief Business Officer

• May 15

  Celsius Therapeutics Launches with $65 Million in Series A Financing to Develop Precision Therapeutics For People with Autoimmune Diseases and Cancer

  Company Created to Understand the Cellular Ecosystem of Disease Through Single-Cell Genomics